Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
Investigational New Drugs · 2024
DOI: 10.1007/s10637-024-01418-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Aaron Shaykevich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Yeshiva University, New York, NY, 10033, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
SMARCA4 is a gene traditionally considered a tumor suppressor. Recent research has however found that SMARCA4 likely promotes cancer growth and is a good target for cancer treatment. The drug carbamazepine, an autophagy inducer, was used on colorectal cancer cell lines, HCT1116 and Hke3 ( KRAS mutant and wildtype). Our study finds that Carbamazepine affects SMARCA4 levels and that this effect is different depending on the KRAS mutation status. This study analyzes the effect of carbamazepine on early-stage autophagy via ULK1 as well as simulates the docking of carbamazepine on KRAS, depending on the mutation status. Our study highlights the therapeutic uses of carbamazepine on cancer, and we propose that carbamazepine in conjunction with other chemotherapies may prove useful in targeting KRAS- mutated colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Yeshiva University, New York, NY, 10033, USA.
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
- Department of Biology, Yeshiva University, New York, NY, 10033, USA. radhashree.maitra@yu.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Shaykevich, A., Chae, D., Silverman, I., Bassali, J., Louloueian, N., Siegman, A., Bandyopadhyaya, G., Goel, S., & Maitra, R. (2024). Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01418-2
Vancouver
Shaykevich A, Chae D, Silverman I, Bassali J, Louloueian N, Siegman A, et al. Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01418-2
BibTeX
@article{Shaykevich2024,
author = {Shaykevich, Aaron and Chae, Danbee and Silverman, Isaac and Bassali, Jeremy and Louloueian, Netanel and Siegman, Alexander and Bandyopadhyaya, Gargi and Goel, Sanjay and Maitra, Radhashree},
title = {Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status},
journal = {Investigational New Drugs},
year = {2024},
doi = {10.1007/s10637-024-01418-2}
}
EUVIMED